Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Pharmaceutical Statistics
|
July 22, 2016
Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development
Kaspar Rufibach, Hans Ulrich Burger, Markus Abt
Therapeutic Innovation & Regulatory Science
|
April 14, 2025
Futility Interim Analyses - A Plea for Simplicity
Gian-Andrea Thanei, Gaëlle Klingelschmitt, Claude Berge, et al.
Biometrical Journal. Biometrische Zeitschrift
|
June 28, 2016
Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: Power, time-to-analysis, and operational aspects
Elina Asikanius, Kaspar Rufibach, Jasmin Bahlo, et al.
Biometrical Journal. Biometrische Zeitschrift
|
July 17, 2019
A multistate model for early decision-making in oncology
Ulrich Beyer, David Dejardin, Matthias Meller, et al.
Pharmaceutical Statistics
|
October 19, 2013
European Federation of Statisticians in the Pharmaceutical Industry's position on access to clinical trial data
Christine Fletcher, Stefan Driessen, Hans Ulrich Burger, et al.
Journal of Biopharmaceutical Statistics
|
April 1, 2024
Estimating treatment effect in randomized trial after control to treatment crossover using external controls
Xiner Zhou, Herbert Pang, Christiana Drake, et al.
Supportive Cancer Therapy
|
July 18, 2008
Effect of treatment with epoetin Beta on thromboembolic events in anemic patients with cancer: a metaanalysis
Bertrand Coiffier, Marc Boogaerts, Matti Aapro, et al.
Journal of Biopharmaceutical Statistics
|
November 9, 2010
Comments on the draft guidance on "adaptive design clinical trials for drugs and biologics" of the U.S. Food and Drug Administration
Werner Brannath, Hans Ulrich Burger, Ekkehard Glimm, et al.
British Journal of Clinical Pharmacology
|
March 13, 2003
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients
Ronald Gieschke, Hans-Ulrich Burger, Bruno Reigner, et al.
Contemporary Clinical Trials
|
May 24, 2014
The use of phase 2 interim analysis to expedite drug development decisions
Jie Huang, Asha Das, Hans Ulrich Burger, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Pharmaceutical Statistics
|
July 22, 2016
Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development
Kaspar Rufibach, Hans Ulrich Burger, Markus Abt
Therapeutic Innovation & Regulatory Science
|
April 14, 2025
Futility Interim Analyses - A Plea for Simplicity
Gian-Andrea Thanei, Gaëlle Klingelschmitt, Claude Berge, et al.
Biometrical Journal. Biometrische Zeitschrift
|
June 28, 2016
Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: Power, time-to-analysis, and operational aspects
Elina Asikanius, Kaspar Rufibach, Jasmin Bahlo, et al.
Biometrical Journal. Biometrische Zeitschrift
|
July 17, 2019
A multistate model for early decision-making in oncology
Ulrich Beyer, David Dejardin, Matthias Meller, et al.
Pharmaceutical Statistics
|
October 19, 2013
European Federation of Statisticians in the Pharmaceutical Industry's position on access to clinical trial data
Christine Fletcher, Stefan Driessen, Hans Ulrich Burger, et al.
Journal of Biopharmaceutical Statistics
|
April 1, 2024
Estimating treatment effect in randomized trial after control to treatment crossover using external controls
Xiner Zhou, Herbert Pang, Christiana Drake, et al.
Supportive Cancer Therapy
|
July 18, 2008
Effect of treatment with epoetin Beta on thromboembolic events in anemic patients with cancer: a metaanalysis
Bertrand Coiffier, Marc Boogaerts, Matti Aapro, et al.
Journal of Biopharmaceutical Statistics
|
November 9, 2010
Comments on the draft guidance on "adaptive design clinical trials for drugs and biologics" of the U.S. Food and Drug Administration
Werner Brannath, Hans Ulrich Burger, Ekkehard Glimm, et al.
British Journal of Clinical Pharmacology
|
March 13, 2003
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients
Ronald Gieschke, Hans-Ulrich Burger, Bruno Reigner, et al.
Contemporary Clinical Trials
|
May 24, 2014
The use of phase 2 interim analysis to expedite drug development decisions
Jie Huang, Asha Das, Hans Ulrich Burger, et al.
Page
of 2